Antiangiogenesis Gene Therapy

Tek Explored for Anticancer Therapeutic Potential

Published in Gene Therapy Weekly, September 21st, 1998

Researchers from Duke University and Regeneron Pharmaceuticals, Inc., explored the endothelium-specific receptor tyrosine kinase Tie2 (Tek) for its potential as an anticancer agent.

Years of research have shown that the ability of a tumor to induce neovascularization determines its rate of growth and also its likelihood of metastases. Therefore, considering the importance of vascular growth in tumor progression, therapeutic approaches targeting this phenomenon may provide long-term, effective control of the disease.

Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide growth factor that has come under close scrutiny by many...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry